Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2026 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2026 · second_quarter · Q2
Source: Senate LDA
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2026 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2025 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2024 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2023 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2023 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2023 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2023 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2022 · fourth_quarter · Q4
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2022 · fourth_quarter · Q4
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2022 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2022 · third_quarter · Q3
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2022 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2022 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2022 · first_quarter · Q1
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2022 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2021 · fourth_quarter · Q4
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2021 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2021 · third_quarter · Q3
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Biopharmaceutical advocacy and educational outreach.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2021 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BRAVO GROUP
2021 · third_quarter · RR
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2021 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2021 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2020 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2020 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2020 · second_quarter · Q2
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2020 · first_quarter · Q1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2019 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2019 · third_quarter · Q3
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2019 · second_quarter · Q2
Biopharmaceutical issues including colon, social, and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2019 · first_quarter · Q1
Biopharmaceutical issues including colon, social, and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2018 · fourth_quarter · Q4
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2018 · third_quarter · Q3
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2018 · second_quarter · Q2
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2018 · first_quarter · Q1
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2017 · fourth_quarter · Q4
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2017 · third_quarter · Q3
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2017 · second_quarter · Q2
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2017 · first_quarter · Q1
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2016 · fourth_quarter · Q4
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2016 · third_quarter · Q3
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2016 · second_quarter · Q2
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2016 · first_quarter · Q1
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2015 · fourth_quarter · Q4
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2015 · third_quarter · Q3
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2015 · second_quarter · Q2
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2015 · first_quarter · Q1
Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2014 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2014 · third_quarter · Q3
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2014 · second_quarter · Q2
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2014 · first_quarter · Q1
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2013 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2013 · third_quarter · Q3
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2013 · second_quarter · Q2
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2013 · first_quarter · Q1
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2012 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2012 · third_quarter · Q3
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2012 · second_quarter · Q2
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2012 · first_quarter · Q1
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2011 · fourth_quarter · Q4
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2011 · third_quarter · Q3
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2011 · third_quarter · 3T
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2011 · third_quarter · Q3
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2011 · second_quarter · Q2
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2011 · second_quarter · 2T
Appropriations
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2011 · second_quarter · Q2
Pharmacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BRAVO GROUP
2011 · second_quarter · RR
Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2011 · first_quarter · Q1
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2011 · first_quarter · Q1
Appropriations
FEDERAL HOME LOAN BANK OF PITTSBURGH via BRAVO GROUP
2010 · fourth_quarter · Q4
Banking
FEDERAL HOME LOAN BANK OF PITTSBURGH via BRAVO GROUP
2010 · fourth_quarter · RR
Outreach
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2010 · fourth_quarter · Q4
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2010 · fourth_quarter · Q4
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2010 · third_quarter · Q3
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2010 · third_quarter · Q3
Appropriatons
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2010 · second_quarter · Q2
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2010 · second_quarter · Q2
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2010 · first_quarter · Q1
Budget
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2010 · first_quarter · Q1
Budget
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2009 · fourth_quarter · Q4
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2009 · fourth_quarter · Q4
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2009 · third_quarter · Q3
Budget
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2009 · third_quarter · Q3
Budget
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2009 · second_quarter · Q2
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2009 · first_quarter · Q1
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2009 · second_quarter · Q2
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2009 · first_quarter · Q1
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2008 · fourth_quarter · Q4
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2008 · third_quarter · Q3
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2008 · second_quarter · Q2
Appropriations
GEISINGER HEALTH SYSTEMS via BRAVO GROUP
2008 · first_quarter · Q1
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2008 · fourth_quarter · Q4
Appropriations
ACADEMY OF NATURAL SCIENCES via BRAVO GROUP
2008 · third_quarter · Q3
Appropriations